Login to Access Video or Poster Abstract: MP27-19
Sources of Funding: None

Introduction

Treatment options for men suffering from lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) include watchful waiting, medications, ablative surgeries, and the Prostatic Urethral Lift (PUL) procedure. We present real-world data from commercial PUL cases using the UroLift ® System.

Methods

PUL involves placing small, permanent, metallic implants (UroLift® System, NeoTract, Inc., Pleasanton, CA) into the prostate under transurethral cystoscopic guidance. The implant is affixed into prostate tissue to lift the lateral lobes away from the urethra and remove obstruction. 197 patients are included in a retrospective analysis on commercial PUL cases performed at multiple centers in Australia and North America. 8% of patients were in urinary retention at the time of the procedure. Post-operative assessments included LUTS relief via International Prostate Symptom Score (IPSS), quality of life (QOL), and peak urinary flow rate (Qmax). Peak flow rates were included in the analysis if the voided volume was at least 75 mL.

Results

Average age was 67 years, range 40-101. Average prostate size was 54.1 cc, range 19-160 cc. Average number of implants was 3.8, range 2-10. LUTS relief was significant, with IPSS demonstrating 29-42% average improvement during the follow up periods (Table 1, p values < 0.0001). Quality of life response was dramatic, with 61% improvement at 1 year (baseline: 4.3, 1 year: 1.7, p value < 0.0001). Peak flow rate improvement was mild throughout.

Conclusions

In clinical studies, the PUL procedure has been shown to be associated with stable and significant symptom relief. We present results from the largest body of commercial data pooled to date and provide insight into real-world application of the minimally invasive PUL therapy. In every day application, PUL offers symptom relief through at least 12 months of follow up.

Funding

None